Sanuwave Health Stock Price, News & Analysis

Sanuwave (NASDAQ: SNWV) will host a live conference call to present its Q3 2025 financial results on Friday, November 7, 2025 at 8:30 AM ET. Telephone access: Toll-Free 1-800-274-8461 or International 1-203-518-9814 with Conference ID SANUWAVE. Instant telephone access is available via the webcast link. Materials will be posted at www.sanuwave.com/investors. A replay will be available through November 28, 2025 via Toll-Free 1-844-512-2921 or 1-412-317-6671 using Replay Access ID 11160405.

Sanuwave Health (NASDAQ: SNWV) announced that CMS published the final 2026 Physician Fee Schedule for CPT code 97610 (UltraMIST) on Oct 31, 2025, and final rates are materially unchanged from 2025.

Reimbursement for physician office, home visits, long-term care, and hospital settings will remain within $2–$4 of 2025 rates, with overall change for 2026 expected to be less than 1%. The company said this aligns with its Oct 6 preliminary revenue expectations and will discuss further on its Q3 earnings call.

Sanuwave (NASDAQ: SNWV) reported preliminary Q3 2025 revenues of $11.4M–$11.6M, the highest quarterly revenue in company history, up 22%–24% vs Q3 2024 and 12%–14% sequentially. First nine months 2025 revenue rose 39%–40% vs YTD 2024. Q3 results missed prior guidance of $12.0M–$12.7M and management lowered 2025 annual revenue guidance from $48M–$50M to $44M–$46M. Company cited near-term reimbursement uncertainty for some wound-care modalities that delayed purchases, but said UltraMIST reimbursement (97610) is not affected and may increase slightly in 2026. Full Q3 2025 results are planned for release on or around November 7, 2025.

Sanuwave Health (NASDAQ: SNWV), a leading provider of FDA-approved wound care products, has successfully refinanced its debt through a new credit facility with J.P. Morgan. The facility includes a $23 million four-year term loan and a $5 million two-year revolving credit facility backed by accounts receivable.

The new arrangement replaces the company's previous $27.5 million debt facility with NH Expansion. At closing, Sanuwave drew approximately $24 million total, including $1 million from the revolving facility. Both facilities carry an interest rate of SOFR +350bp with no prepayment penalties. The remaining balance and transaction costs of approximately $4.8 million were paid using operational cash flow and proceeds from a recent patent sale.

Sanuwave Health (NASDAQ: SNWV) reported strong Q2 2025 financial results, achieving record quarterly revenues of $10.2 million, up 42% year-over-year. The company demonstrated improved profitability with a gross margin of 78.3%, up from 73.2% in Q2 2024.

Key highlights include the sale of 116 UltraMist® systems in Q2 2025, up from 72 in Q2 2024, and UltraMist® consumables revenue increased by 37% to $6.4 million. Operating income was $1.9 million, with net income of $1.1 million. The company achieved Adjusted EBITDA of $3.4 million, more than double the $1.5 million from Q2 2024.

Looking ahead, Sanuwave provided guidance for Q3 2025 revenue of $12-$12.7 million and maintained its full-year 2025 revenue guidance of $48-$50 million, representing a 47-53% increase from 2024.

Sanuwave Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss its Q2 2025 financial results on Friday, August 8, 2025, at 8:30 AM ET.

Investors can access the call via toll-free number 1-800-245-3047 or international number 1-203-518-9765 using Conference ID: SANUWAVE. A webcast link is also available. Presentation materials will be accessible on the company's investor relations website, and a replay will be available through August 29, 2025.

Sanuwave Health (NASDAQ: SNWV), a provider of FDA-approved wound care products, announced that CEO Morgan Frank will present at the 45th Annual Canaccord Genuity Growth Conference. The presentation is scheduled for August 13, 2025, from 9:30 to 9:55 a.m. ET at the InterContinental Hotel in Boston.

Sanuwave specializes in non-invasive medical systems for regenerative medicine, focusing on skin, musculoskeletal tissue, and vascular structure repair. The company's technology portfolio includes patented energy transfer technologies applied in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Sanuwave Health (NASDAQ:SNWV), a leading provider of FDA-approved wound care products, reported preliminary Q2 2025 revenues of $10.1-$10.2 million, marking its highest Q2 revenue in company history. This represents a 41-42% increase compared to Q2 2024.

The company has undergone significant commercial expansion, including the appointment of a new head of sales and commercial operations. By July, Sanuwave will have 13 sales representatives covering all national territories, plus a dedicated national accounts manager for larger opportunities. The first half of 2025 showed strong performance with a 50-51% revenue increase compared to the first half of 2024.

Full Q2 2025 results will be released around August 8th, 2025.

Sanuwave Health (NASDAQ:SNWV) has appointed Dustin Libby as Executive Vice President of Commercial Operations. Libby brings 20 years of medical device industry experience, with a strong track record in commercial growth and sales operations. His notable achievement includes scaling Abiomed's surgical business from $15M to over $500M in revenue as director of commercial operations. Libby's extensive experience includes leadership roles at Smith & Nephew, Arthrex, and Hill-ROM, where he managed sales enablement, operational strategy, KOL development, and product launches. CEO Morgan Frank emphasized Libby's experience in scaling teams and systems as crucial for Sanuwave's growth plans in the wound care market. Libby, who holds a B.S. in Product Design & Development from Keene State College, commenced his role on June 3, 2025.